Cervical cancer is the second most common cancer in women after breast cancer. In nearly all cases, the patient has a history of infection with human papilloma virus (HPV). Two types of cervical cancer, squamous cell cancer and adenocarcinoma are known to be caused by HPV.
There are as many as 100 different types of HPV; most do not cause significant disease in humans. High risk types of HPV (6, 11, 16 and 18) can cause changes in the cells covering the cervix that make them more likely to become cancerous in time. Approximately 70% of cervical cancer resulting from HPV 16, and 18 would be preventable by using the currently available vaccines.
The Pap test (or Pap smear) has helped diagnose many women with cervical cancer or pre-cancerous conditions. HPV testing is as a way of distinguishing women who have a higher risk of developing cervical cancer from those who have very low risk.
There are a number of immunodiagnostic tests available such as competitive radioimmunoassays (cRIAs), competitive luminex-based immunoassay (cLIA) and enzyme-linked immunosorbent assays (ELISAs). Methods have been developed to measure neutralizing antibody responses to HPVs: in vivo neutralization assays, in vitro pseudoneutralization assays and ELISAs measuring antibodies produced to HPV Virus-Like Particles.
Our range includes the following anti-HPV antibodies, all available in bulk for manufacture of immunodiagnostic tests.
|Papillomavirus 11 Protein E7||Purified||711-66||MCA2852|
|Papillomavirus 16 Oncoprotein E7||Purified||716-D1||MCA2818|
|Papillomavirus 16 Oncoprotein E7||Purified||716-F10||MCA2819|
|Papillomavirus 18 Oncoprotein E7||Purified||718-15||MCA2820|
|Papillomavirus 18 Oncoprotein E7||Purified||718-238||MCA2821|